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Abstract
Background: Osteosarcoma (OS), which has a high potential for developing metastatic disease, is the most
frequent malignant bone tumor in children and adolescents. Molecular analysis of a metastatic genetically
engineered mouse model of osteosarcoma identified enhanced expression of Secreted Frizzled-Related Protein 2
(sFRP2), a putative regulator of Wnt signaling within metastatic tumors. Subsequent analysis correlated increased
expression in the human disease, and within highly metastatic OS cells. However, the role of sFRP2 in osteosarcoma
development and progression has not been well elucidated.
Methods: Studies using stable gain or loss-of-function alterations of sFRP2 within human and mouse OS cells were
performed to assess changes in cell proliferation, migration, and invasive ability in vitro, via both transwell and 3D
matrigel assays. In additional, xenograft studies using overexpression of sFRP2 were used to assess effects on in vivo
metastatic potential.
Results: Functional studies revealed stable overexpression of sFRP2 within localized human and mouse OS cells
significantly increased cell migration and invasive ability in vitro and enhanced metastatic potential in vivo. Additional
studies exploiting knockdown of sFRP2 within metastatic human and mouse OS cells demonstrated decreased cell
migration and invasion ability in vitro, thus corroborating a critical biological phenotype carried out by sFRP2.
Interestingly, alterations in sFRP2 expression did not alter OS proliferation rates or primary tumor development.
Conclusions: While future studies further investigating the molecular mechanisms contributing towards this sFRP2-
dependent phenotype are needed, our studies clearly provide evidence that aberrant expression of sFRP2 can
contribute to the invasive and metastatic potential for osteosarcoma.
Background
Osteosarcoma is the most common frequent malignant
bone tumor within the pediatric population [1, 2]. Me-
tastasis to the lungs or other bones is a poor prognostic
indicator with long term overall survival rate of 10–30 %
[3, 4]. Understanding disease biology and the molecular
signaling pathways involved in osteosarcoma develop-
ment and progression should lead to the identification
of novel therapeutic targets.
The Wingless (Wnt) signaling pathway is involved in
normal embryonic development [5, 6]. Wnt activity is
regulated at the cell membrane by a complex network of
transmembrane proteins [7, 8]. For the canonical signal-
ing pathway, binding of Wnt ligands to Frizzled recep-
tors, which are G protein-coupled receptors, leads to
activation and translocation of β-catenin from the cyto-
plasm to nucleus. Subsequent binding to T cell factor
(TCF)/lymphoid enhancer factor (LEF) leads to tran-
scriptional activation of downstream target genes [9, 10].
However, aberrant activation of Wnt signaling pathways
has been reported in many types of cancer including
colorectal, brain, and sarcomas [7, 11].
The Wnt signaling pathway is partially regulated by
extracellular Wnt antagonists, consisting of members of
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Dickkopf and secreted Frizzled-related proteins (sFRPs)
families, and Wnt inhibitory factor 1 [12, 13] The sFRP
family consists of five different glycoproteins (sFRP1-5),
each containing a highly homologous cysteine-rich do-
main and putative binding site on the Frizzled receptor
binding site used by the Wnt ligands. Consequently, the
role of sFRPs has been predominantly focused on pre-
venting Wnt ligands from binding the Frizzled receptors,
which results in Wnt signaling downregulation [9, 14].
Specifically, using insights gained from our genetically
engineered mouse model (GEMM) of metastatic OS and
correlative human studies, we have identified aberrant
expression of sFRP2 in metastatic osteosarcoma [15].
The dysregulation of sFRP2 has been reported in several
malignancies, however the mechanisms by which it con-
tributes to the biology of these cancers has been variable.
For instance, sFRP2 is noted to be downregulated via
epigenetic hypermethylation in human gastric cancer
[16], colorectal cancer [17, 18], and oral squamous cell
carcinoma [19, 20] suggesting a role as a tumor suppres-
sor. However, overexpression of sFRP2 has been reported
in renal cancer [8], human angiosarcoma, and breast can-
cer [21, 22], which leads to angiogenesis stimulation by ac-
tivation of the calcineurin/NFATc3 pathway. Furthermore,
recently enhanced sFRP2 expression has been associated
with promoting therapeutic resistance and metastatic po-
tential within solid tumors by specifically altering the
tumor microenvironment [23, 24].
To our knowledge, the functional significance of
sFRP2 in osteosarcoma has not been well studied. Our
studies provide insights into the functional role of sFRP2
within osteosarcoma tumor development and metastasis.
We demonstrate that sFRP2 expression strongly en-
hances metastatic potential both in vitro and in vivo, but
has no noted effects on tumor cell proliferation or pri-
mary tumor development. Further studies are warranted
to investigate the exact mechanisms of action for
sFRP2 and its regulation of metastatic pathways for
osteosarcoma.
Methods
Cell culture and transfections
Highly metastatic mouse OS cell lines (RF379L, and
RF1044) were derived from either p53+/R172H or p53
null OS mouse models primary OS tumors and/or lung
lesions using our previously established, highly metastatic
Col2.3-Cre transgenic mice with osteoblast-specific Cre
expression. Low metastatic mouse OS cell line (RF43) was
isolated from singly floxed p53+/F-Col2.3-Cre mice as
previously reported [15]. All cell lines used for functional
assays were extensively characterized for their migratory,
invasive, and metastatic potentials both in vitro and in
vivo prior to genetic alteration, overexpression or knock-
down, of SFRP2 status.
The human osteosarcoma cell lines, HOS and 143B
were purchased from ATCC (Manassas, VA, USA). All
human cell lines used in these studies were authenti-
cated through STR analysis at MD Anderson (https://
www.mdanderson.org/research/research-resources/core-
facilities/characterized-cell-line-core-facility.html) and
were tested and remained free of mycoplasma. All cells
were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10 % Fetal Bovine Serum
(FBS) and 1 % penicillin/streptomycin (GIBCO, Life
Technology, Grand Island, NY USA). All cells were
allowed to grow in a humidified 37 °C, 5 % CO2 in-
cubator. Stable control or sFRP2 knockdown cell lines
were generated by transfecting Open Biosystems/GE
Dhramacon pLKO.1 TRC control or pLKO.1 shsFRP2
vector (Clone ID: TRCN0000034474; Clone ID:
TRCN0000034476) utilizing the Lipofectamine LTX
reagent (Invitrogen). Positively transfected clones were
selected with puromycin (2ug/mL), and real-time PCR
confirmed sFRP2 knockdown. FlexiTube (QIAGEN,
catalogue# GS12393) siRNA for sFRP2 was transfected
per manufacturer’s recommendation. Stable mouse and
human cell lines overexpressing sFRP2 were generated by
transfecting a sFRP2 or empty vector (pcDNA3.1) using
the Lipofectamine LTX reagent, and positively transfected
clones were selected using neomycin (1 mg/mL).
RNA extraction and reverse transcription-PCR
Total RNA was extracted using the RNAeasy Mini
Kit (Qiagen) according to manufacturer’s instructions.
cDNA templates were generated by 1 μg of total
RNA via RT—PCR using cDNA Synthesis Supermix
(Quanta, Gaithersburg, MD, USA). The cDNA prod-
ucts were used for real-time PCR templates. Gene ex-
pression was monitored using real-time primer pairs
with SYBR Green detection (Applied Biosystems, Life
Technology) and analyzed using StepOnePlus real-
time PCR machine (AB Biosystems, Life Technology).
PCR conditions were as follows: 10 min at 95 °C and
60 s at 60 °C. Relative fold change in mRNA expres-
sion compared with control was calculated using
ΔΔCT method. All samples were normalized to actin
expression level.
Cell proliferation assay
To assess cell proliferation, 1 × 103 cells/well were
seeded in a 96 well plate in 100 μl cell culture medium.
Cells were cultured in a 5 % CO2 incubator at 37 °C. At
indicated time points, viable cells were counted using
Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto,
Japan) following the manufacturer’s protocol. The rela-
tive proliferation rates were determined by measuring
the absorbance at 450 nm using a Perkin Elmer Victor2
microplate reader. Individual time points were run in
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triplicates. Each experiment was performed at least
twice, with representative results shown.
Cell migration assay
Cell lines, both control and sFRP2 altered, were cultured
to confluence in six-well plates. Using a sterile 200-μl
pipette tip, a scratch was drawn on the monolayer of the
cells. The cells were then washed once with phosphate-
buffered saline (PBS). Time points for analysis are indi-
cated within figures. Assay was performed three inde-
pendent times with representative images shown.
In vitro invasion assay
The in vitro invasion assay was performed using 24-well,
8 μm pore-sized invasion chamber system (Greiner
BioOne, Monroe, NC, USA) and 0.5 μg/ml collagen
(Advanced Biomatrix, Carlsbad, CA, USA) monolayer.
Prior to loading the cells onto the upper chamber, the
lower chamber was filled with medium containing 10 %
FBS. Cells were starved overnight and added to serum
free medium in the upper chamber at the concentration
of 1 × 105 cells/well followed by incubation for 12–18 h
in a humidified 5 % CO2 atm at 37 °C. After incubation,
the cells on the upper surface of the well were removed
completely by Q-tip. The wells were fixed in methanol
and strained with 15 % crystal violet (Alfa Aesar, Ward
Hill, MA, USA). The number of cells migrating to the
lower surface of the filters were counted in five fields
under 20X magnification and the mean of the number
of cells in each well was calculated. Assays were per-
formed three independent times with representative im-
ages shown.
3D cell morphology assay
Cells were trypsinized, placed in complete media,
counted and then 105 osteosarcoma cells were mixed
with 3 % Matrigel in complete medium. Suspended cells
were loaded into 12-well plates, allowed to polymerize at
37 °C, and then overlaid with complete media. After
72 h, phase-contrast images were taken. Assays were
performed three independent times with representative
images shown.
In vivo studies
Mouse studies were approved by Baylor Animal Protocol
Committee (Baylor College of Medicine Animal Protocol
AN-5225. Suspensions of the stable sFRP2-expressing
cell or the control cell RF43, a low metastatic cell line
derived from our previously reported GEMM [15], were
injected subcutaneously into female nu/nu mice (n = 6/
cohort). Tumor size was measured with calipers once
per week for six weeks and the tumor was weighed at
the time of mouse sacrifice. All animals had comprehen-
sive necropsies upon time of euthanasia with complete
dissection of tumor as well as evaluation of all major or-
gans, with special attention given to the lungs, liver and
other bones. Portions of all tumor specimens and that of
the lungs and liver were sent for histological analysis
and evaluation of distal organs for evidence of metastatic
disease. The lungs were the main site of metastasis, and
lung metastatic nodules were visualized on 5 μm
paraffin-embedded sections with H&E staining and were
quantified.
Western blotting
Cells were lysed in RIPA buffer (50 mM Tris-Cl, pH 7.4,
150 mM NaCl, 1 % NP-40, 0.25 % Na-deoxycholate)
supplemented with protease inhibitors (Complete mini
protease cocktail, Roche, Indianapolis, IN, USA) and
phosphatase inhibitors (Sigma, P0044 and P5726). Nu-
clear lysates were isolated utilizing the NE-PER nuclear
and cytoplasmic extraction reagents (Promega) following
the manufacturer’s instructions. Lysates were boiled in
NuPAGE LDS sample buffer (Invitrogen), separated on
NuPAGE Novex 4–12 % Bis-Tris Gel (Invitrogen), and
transferred to polyvinylidene difluoride membranes. The
blots were probed with antibodies to sFRP2 (Company),
tubulin (Fisher Scientific, Waltham, MA, USA, Ab-2,
clone DM1A), or actin (EMD Millipore, Billerica, MA,
USA, MAB1501, clone C4). Blots were incubated with
the appropriate secondary HRP-conjugated antibodies
for 1 h, and signal was detected utilizing Millipore
Immobilon Western chemiluminescent HRP substrate
(Millipore).
Statistical analysis
The significance of differences between control and
sFRP2 samples under different conditions was deter-
mined by Student’s t-test. P values less than 0.05 were
considered statistically significant. Data are shown as
mean value +/− SD.
Results
Identification of increased sFRP2 expression in metastatic
osteosarcoma
We have previously developed and characterized a gen-
etically engineered mouse model of metastatic osteosar-
coma [15] that revealed differential expression of several
categorical genes within the primary metastatic tumors,
including those involved in translational regulation, in-
flammation, and regulation of Wnt signaling. Specific-
ally, besides the downregulation of the negative
regulators Naked2 (Nkd2) and Apcdd1, we also noted
enhanced, approximately three-fold expression of sFRP2
[15]. sFRP2 is a member of a family of extracellular sig-
naling molecules involved in the regulation of the Wnt
pathway. Besides our findings, recent literature has also
reported enhanced expression of sFRP2 in angiosarcoma
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and breast cancer, and analysis of multiple publicly avail-
able datasets (cBioPortal for Cancer Genomics, http://
www.cbioportal.org) revealed relatively elevated levels of
sFRP2 in sarcomas (Additional file 1: Figure S1a; red
box highlighting sarcomas).
To validate our initial expression profiling data, we
performed qPCR of independent local and primary
metastatic mouse tumors and noted significant en-
hanced expression of sFRP2 in the metastatic tumors
(Fig. 1a). Exploration of sFRP2 expression in human
osteosarcoma revealed enhanced expression compared
to mesenchymal stem cells (MSCs) (Fig. 1b) [25]. We
further examined the relative expression of sFRP2 in
human osteosarcoma tumor specimens and cell lines.
We analyzed human osteosarcoma specimens of 7
metastatic (the primary bone tumor from a patient
with metastatic disease) and 4 non-metastatic tumors
as well as established paired cell lines HOS and 143B.
As shown in Fig. 1c and d, sFRP2 is significantly up-
regulated in the primary bone tumor from patients
with metastatic disease compared to tumors from pa-
tients with only localized disease, and within the
highly metastatic human osteosarcoma cell line 143B
compared to its paired cell line HOS that has low
metastatic potential. In summary, these results pro-
vide evidence supporting increased expression of
sFRP2 in metastatic OS.
Besides the enhanced expression observed in meta-
static OS, using the publically available R2 database
(http://hgserver1.amc.nl/cgi-bin/r2/main.cgi), we investi-
gated whether sFRP2 expression also has clinical rele-
vance for sarcomas, as increased mRNA expression
levels are significantly associated with poorer event
free and overall survival for Ewing sarcoma, the sec-
ond most common pediatric bone tumor (Additional
file 1: Figure S1b and c).
sFRP2 overexpression enhances osteosarcoma cell
migration and invasion in vitro
After identifying and confirming differential expression
of sFRP2 in mouse and human metastatic OS, and its
clinical relevance for patients with bone sarcomas, our
goal was to elucidate the phenotypic effects of sFRP2 on
osteosarcoma. We expressed sFRP2 in low-metastatic
mouse and human osteosarcoma cell lines, RF43
(designated as sFRP2/RF43) and HOS (designated as
sFRP2/HOS). As shown in Figs. 2 and 3, cell prolifera-
tion assays for both mouse and human showed similar
proliferation rates comparing control and overexpression
of sFRP2 (Figs. 2a and 3a). Interestingly, sFRP2/RF43
and sFRP2/HOS revealed enhancement of invasive and
migratory potential by scratch and transwell assays when
compared with control cells (Figs. 2b,c and 3b,c). Fur-
thermore, when placed in 3D matrigel culture assay, we
Fig. 1 Enhanced expression of sFRP2 in metastatic osteosarcoma. a qPCR analysis of sFRP2 expression in mouse non-metastatic and metastatic
osteosarcoma cell lines. b Analysis of GEO database GSE42352 for sFRP2 expression in human osteosarcoma tumors compared to mesenchymal
stem cells. c qPCR analysis comparing expression of sFRP2 in metastatic primary human osteosarcoma tumor tissue to non-metastatic tumor.
d qPCR analysis for human sFRP2 comparing low metastatic (HOS) versus high metastatic (143B) paired OS cell lines
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observed sFRP2/HOS cells demonstrated enhanced inva-
sive potential (Fig. 3d). Therefore, our data provide con-
vincing evidence that enhanced, dysregulated expression
of sFRP2 has pro-invasive properties.
SFRP2 knockdown in metastasis osteosarcoma cell line
decrease cells migration and invasion in vitro
After demonstrating that enhanced sFRP2 expression
contributes towards OS migratory and invasive potential
in vitro, we next investigated the effects of reducing
sFRP2 in highly metastatic osteosarcoma cells. After
generation of stable knockdown of sFRP2 in two inde-
pendent metastatic mouse osteosarcoma cell lines,
RF1044 and RF379L, cell proliferation assays showed
similar proliferation profiles in knockdown and control
cell lines (Fig. 4a, Additional file 2: Figure S2a). However,
knockdown of sFRP2 in highly metastatic mouse cells
showed decreased invasive and migratory potential by
scratch and transwell assays when compared with con-
trol cells (Fig. 4b,c, Additional file 2: Figure S2b,c).
Furthermore, matrigel 3D culture assay of sFRP2 knock-
down RF1044 cells also revealed reduced projections
and decreased invasive potential compared with control
cells (Fig. 4d). Therefore, our results demonstrate that
decreased levels of sFRP2 decrease migratory and inva-
sive ability of OS cells. Overall our in vitro data provide
sound evidence that alterations in sFRP2 expression do
not alter proliferation profiles of OS cells, but contribute
towards metastatic properties through modification of
migratory and invasive properties.
SFRP2 overexpression enhanced osteosarcoma metastatic
potential in vivo
Overall our in vitro studies clearly highlight the promin-
ent effects sFRP2 has on migratory and invasive proper-
ties. However, we next wanted to determine the effects
of sFRP2 expression on OS cells in vivo. Subcutaneous
injection of sFRP2/RF43 cells was performed in nude
mice and tumor growth was evaluated. At 8 weeks after
transplantation, average size and weight of vector con-
trol RF43 and sFRP2/RF43 tumors were not statistically
different (Fig. 5a). However, comprehensive gross exam-
ination of sFRP2/RF43 mice showed increased develop-
ment of distal lung metastatic lesions. Lung metastases
were identified in mice in sFRP2/RF43 mice but minimal
evidence of metastatic disease was found in the control
Fig. 2 Enhanced sFRP2 expression in non-metastatic mouse OS cells does not alter proliferation, but promotes increased migratory and invasive
properties. a CCK-8 cell proliferation assay of sFRP2/RF43 and vector control cells. Western blot analysis of whole cell lysates showing expression
of sFRP2 in control and sFRP2-overexpressing cells. Actin shown as loading control. b Cell migration assay of sFRP2/RF43 and control RF43 cells.
c Transwell invasion assay of sFRP2/RF43 and control RF43 cells. Crystal violet staining for control and sFRP2 expressing cells is shown. Quantification of
tumor cell invasion is shown to the right
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group (Fig. 5b). H&E images of a lung metastasis is
shown in Fig. 5c, clearly showing a prominent metastatic
OS nodule.
Discussion
The role of the secreted Frizzled related family of pro-
teins has predominantly been associated with regulation
of the Wnt signaling pathway. Specifically, studies in
several malignances have demonstrated downregulation
of sFRP2 via epigenetic promoter hypermethylation, sug-
gesting a possible role as a tumor suppressor [26, 27].
However, recently reports provide evidence that sFRP2
can enhance tumor aggressiveness or progression in
several cancers, including melanoma, renal cancer,
angiosarcoma, and breast cancer. Specifically within
angiosarcoma, studies have shown that sFRP2 enhances
tumorigenesis as inhibitory antibodies directed towards
sFRP2 have demonstrated anti-tumor effects [21]. In
addition, sFRP2 can contribute towards therapeutic
resistance through indirect activation of beta-catenin
and non-canonical pathways [24].
Interestingly, sFRP2 has been reported to have a crit-
ical role in mesenchymal stem cell biology, with induced
expression observed in MSCs by activation of the PI3K-
Akt pathway [28, 29]. Furthermore, induction of sFRP2
enables maintenance of mitochondrial function and pro-
vides anti-apoptotic effects [29] as well as paracrine ef-
fects involved in myocardial survival and repair [30].
However the role of sFRP2 in mesenchymal tumor
biology, such as osteosarcoma, remains to be eluci-
dated. A recent report of sFRP2 suggests it provides
anti-invasive functions in OS, but this report provides
little direct evidence of sFRP2 function [31]. Within
this report, anti-invasive properties were only demon-
strated after use of 5’aza-cytidine, or decitabine, a
broad, non-specific hypomethylating agent that can
cause significant global alterations in cellular gene
regulation.
Fig. 3 Overexpression of sFRP2 in low metastatic human OS cells drives increased invasive potential. a CCK-8 cell proliferation assay of sFRP2/
HOS and HOS vector control cells. Western blot analysis of whole cell lysates showing expression of sFRP2 in control and stable clones. b Cell
migration assay of sFRP2/HOS and control HOS cells. c Transwell invasion assay of control HOS (top) and sFRP2/HOS (bottom) cells. Crystal violet
staining for control and sFRP2 expressing cells is shown. Quantification of tumor cell invasion is shown to the right. d 3D matrigel assay for vector
control (top panel) and sFRP2/HOS cells (bottom panel)
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We believe our in vitro and in vivo studies provide dir-
ect molecular evidence that sFRP2 expression signifi-
cantly contributes to OS metastatic phenotype. In our
studies, we have demonstrated that sFRP2 has enhanced
expression in metastatic mouse and human osteosar-
comas. We specifically focused on the direct biological
effects of sFRP2 on OS by using gain and loss-of-
function experiments that revealed sFRP2 expression has
no observable effect on tumor cell proliferation both in
vitro and in vivo. In contrast, stable expression of sFRP2
significantly promotes migratory and invasive potential
of OS cells both in vitro and in vivo. While we report
that gain-of-function sFRP2 enhanced metastatic poten-
tial in vivo, when we attempted to silence sFRP2 expres-
sion in metastatic OS cells in xenograft models, we
obtained only modest decrease of metastatic potential
(data not shown). This suggests that enhanced sFRP2 ex-
pression may be sufficient to drive metastatic phenotype,
but other factors, including alterations in other Wnt
modulators (as reported in our prior publication) [15]
may be compensating for the knockdown of sFRP2 in
vivo. Further molecular studies are warranted, including
a more analysis of the in vivo sFRP2 knockdown tumors
(versus control) might provide insights into compensa-
tory mechanisms ongoing in vivo that could still be driv-
ing the metastatic state.
While we believe our studies provide significant con-
tributions towards understanding metastatic mecha-
nisms for osteosarcoma, further studies are warranted to
investigate direct downstream molecular mechanisms
associated with sFRP2 expression. In order to investigate
a possible mechanism of the sFRP2-dependent pheno-
type, we performed Wnt signaling reporter studies upon
alteration of sFRP2 in the OS cells, but observed no sta-
tistically significant changes in canonical Wnt activation
(data not shown). Investigations into additional signaling
cascades could provide novel insights into the direct role
of sFRP2 and metastatic mechanisms for osteosarcoma.
Fig. 4 Knockdown of sFRP2 in metastatic mouse cells decreases in vitro migratory and invasive potential for OS. a CCK-8 cell proliferation assay
of multiple shsFRP2/RF1044 and RF1044 vector control cells. Western blot analysis showing expression of sFRP2 in control and knockdown cells.
b Cell migration assay of shsFRP2/RF1044 and control RF1044 cells. c Transwell invasion assay of control RF1044 (left panel) and shsFRP2/RF1044
(right panel) cells. Crystal violet staining for control and shsFRP2 expressing cells is shown. Quantification of tumor cell invasion is shown to the
right. d 3D matrigel assay for vector control (top panel) and shsFRP2/RF1044 cells (bottom panel)
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Besides the aforementioned PI3K-Akt pathway, add-
itional candidate mechanisms include the possibility that
sFRP2 could positively regulate the expression of the
stem cell transcription factor Slug [32], which is involved
promoting the metastatic phenotypes of carcinomas
[33]. Studies into if sFRP2 could alter the differentiation
or stemness of osteosarcoma cells would also be inter-
esting to investigate.
Finally, using our pre-clinical engineered and orthoto-
pic mouse models, investigations into the ability to
therapeutically target sFRP2 within OS would be ex-
tremely interesting. Presently there are pre-clinical
monoclonal antibodies targeting sFRP2 [21], which
could provide biological evidence for the role of this
molecule on sarcoma progression.
Conclusions
While many of the negative regulators of Wnt signaling
pathway have been implicated in inhibiting the develop-
ment and progression of OS, we have identified and
characterized a sFRP family member, specifically sFRP2,
which is enhanced within metastatic OS. Our studies
provide significant insights into a potential unique role
for sFRP2 as a novel pure driver of invasive and
metastatic phenotypes for this disease. Both our in vitro
and in vivo gain and loss-of-function studies indicate
that sFRP2 expression has no significant effects on
tumor cell proliferation, but clearly dictates invasive and
migratory phenotypes and enhances metastatic potential.
We believe these studies will provide the foundation for
additional molecular studies as well as avenues for novel
therapeutic intervention.
Additional files
Additional file 1: Figure S1. Relative sFRP2 expression across panel of
tumors and sarcoma survival outcomes associated with sFRP2 expression.
a. TCGA data comparing relative expression of sFRP2 (cBioPortal for
Cancer Genomics, http://www.cbioportal.org) across a panel of different
tumor types demonstrating high expression in sarcomas (8th of 26 tumor
types). b and c. EFS and overall survival scans for sFRP2 derived from
clinically annotated human Ewing sarcoma gene expression database
(http://hgserver1.amc.nl/cgi-bin/r2/main.cgi). High expression (blue line)
and low expression (red line). (PDF 330 kb)
Additional file 2: Figure S2. Knockdown of sFRP2 in metastatic mouse
cells decreases in vitro migratory and invasive potential for OS a. CCK-8
cell proliferation assay of shsFRP2/RF379L and RF379L vector control cells.
Western blot analysis of whole cell lysates showing expression of sFRP2
in control and knockdown cells. b. Cell migration assay of shsFRP2/
RF379L and control RF379L cells. c. Transwell invasion assay of control
RF379L (top panel) and shsFRP2/RF379L (bottom panel) cells. (PDF 203 kb)
Fig. 5 sFRP2 promotes OS metastasis, but not primary tumor growth, in vivo. a Representative images of primary implanted tumors and tumor
mass (in grams) sacrificed at 8 weeks for control RF43 and sFRP2/RF43 cells. b Representative gross images of lungs from RF43 control and
sFRP2/RF43 injected mice (left panels, black arrows indicate macroscopic lung lesions). Quantification of lung nodules shown in graph (right
panel) (c). Representative H&E images from lungs of RF43 control and sFRP2/RF43 injected mice. Black arrow indicates metastatic lung nodule
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